Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL30852696 | 1.00 | TSHR (0.47) | TSHRTP53EGLN1EGLN3POLB | |
| Fumaric Acid SCHEMBL14636010 | 0.90 | SMN1; SMN2 (0.45) | TSHRTP53EGLN1EGLN3POLB | |
| Maleic Acid SCHEMBL14636006 | 0.90 | SMN1; SMN2 (0.45) | TSHRTP53EGLN1EGLN3POLB | |
| Cyclohexane Carboxamide SCHEMBL6642170 | 0.88 | SMN1; SMN2 (0.48) | TSHRTP53EGLN1EGLN3POLB | |
| Cyclohexane Carboxamide SCHEMBL6642173 | 0.88 | SMN1; SMN2 (0.48) | TSHRTP53EGLN1EGLN3POLB | |
| Cyclohexane Carboxamide SCHEMBL14636301 | 0.88 | SMN1; SMN2 (0.48) | TSHRTP53EGLN1EGLN3POLB | |
| Cyclohexane Carboxamide SCHEMBL27390669 | 0.86 | SMN1; SMN2 (0.47) | TSHRTP53EGLN1EGLN3POLB | |
| Maleic Acid SCHEMBL4261390 | 0.84 | TSHR (0.52) | TSHRTP53EGLN1EGLN3POLB | |
| Fumaric Acid SCHEMBL4261402 | 0.84 | TSHR (0.52) | TSHRTP53EGLN1EGLN3POLB | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL8743189 | 0.83 | SMN1; SMN2 (0.46) | TSHRSMN1; SMN2GAAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975008-B2 | Pharmaceutical compositions comprising a JAK inhibitor | GALAPAGOS NV (BE) | 2024-05-07 | — | — | US | disclosed |
| EP-3595667-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR | GALAPAGOS NV (BE) | 2023-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975008-B2 | Pharmaceutical compositions comprising a JAK inhibitor | JAK1, JAK3, JAK2 | ACE 4683/4885TSHR 2130/4885TP53 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.